On July 16, 2024, the Company’s board of directors approved a reduction of the Company’s workforce to conserve cash resources. The workforce reduction affected 47 people, or approximately 40% of the Company’s headcount. The Company incurred $0.9 million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance payments, benefits and related costs. The Company completed the workforce reduction plan and all the related cash payments during the third quarter ended September 30, 2024.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics price target lowered to $4 from $17 at Wells Fargo
- Rapt Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- JPMorgan cuts Rapt Therapeutics to Underweight after zelnecirnon discontinued
- Rapt Therapeutics downgraded to Underweight from Neutral at JPMorgan
- Rapt Therapeutics model under review at Stifel after zelnecirnon discontinued